bilocelhi Posted - 12 hours ago

$BDTX looking good here! Expect buyout by eoy

Bigeyes2 Posted - 16 hours ago

$BDTX

ViractaTrader77 Posted - 22 hours ago

$BDTX $STRO Abbvie bought similar ADC for $10 billion. $ELEV $OPK

SPP27 Posted - 3 days ago

$BDTX keeg going ⬆️🔥

RallyRaider Posted - 3 days ago

$BDTX think 10

ParsecTI994A Posted - 5 days ago

$BDTX Given that Patrick Wen and Yoshie Umemura are speakers for the Glioblastoma posters I’m assuming the data is at least promising on that front. No fear of another BDTX-189 collapse this ASCO. Hopefully it’s awesome data but glioblastoma is so hard.

Stock_Titan Posted - 5 days ago

$BDTX Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting https://www.stocktitan.net/news/BDTX/black-diamond-therapeutics-announces-presentations-at-the-2024-dndcysbhfirm.html

Smoovem80 Posted - 6 days ago

$BDTX why does the price of this stock in my E*trade account say it’s $0.00? Anyone else seeing this on their platform?

Smoovem80 Posted - 1 week ago

$SPY I hope Israel blows the shit out of that country. I’m also extra proud I’ve got 770k in t bills right now. Trade account empty w equities except 10k in $BDTX.

_www_larval_com_ Posted - 1 week ago

$BDTX just slipped -3% lower to -7% (~1Mv) moments ago, 04/19 options, follow for more volatility.

questionable1 Posted - 1 week ago

$BDTX thinking there might be a nice push into the $7s today! Next week or two double digits. Earning may 7 pre market!!

victorcastro Posted - 1 week ago

$QQEW $QQQ $TRAN $ASML $BDTX

ParsecTI994A Posted - 1 week ago

$BDTX

Stocktwits Posted - 1 week ago

Added $BDTX to watchlist ⌚️

Stocksrunner Posted - 1 week ago

Wednesday's Remarkable Rebounds: Stocks Surging from Open to Close 💹 🚀 $BDTX Builds Momentum BDTX opened the market at $5.32, escalating to $5.98, reflecting a solid 12.41% change.

Wilder992001 Posted - 1 week ago

$BDTX I’ll take it got in at $3.00 I’ll keep adding more to come from this one.

Smoovem80 Posted - 1 week ago

$BDTX they get a partner or something? What’s the deal?

ACInvestorBlog Posted - 1 week ago

$BDTX finally breaking out

vjtweet Posted - 2 weeks ago

$BDTX on this week's long watch.

questionable1 Posted - 2 weeks ago

$BDTX wow more ppl starting to show up early to the party, its gonna be a good one! $40+ EOY

Jafo333isme Posted - 2 weeks ago

$BDTX LOL - ya'll can thank me for slapping the ask in AH and raising the price from 5 to 5.33 🤣🤣🤣 the f#ing spread was 60 cents!

ViractaTrader77 Posted - 2 weeks ago

$BDTX $CRBP Sutro Bio has almost $6 in current assets in cash per share. Big deals with Merck, Vaxcyte, Ispen Pharma and Astellas. And a similar ADC company targeting Folate Receptor with earlier asset just got bought for $1.8 billion. It's the second acquisition in folate receptor first one was Immunogen. Steve Cohen and Ispen Pharma just invested heavily at $5.18 per share. $ELEV $NVDA https://x.com/SutroBio/status/1775949657774112893

Wilder992001 Posted - 2 weeks ago

$BDTX All Aboard! I'm in!

questionable1 Posted - 3 weeks ago

$BDTX been watchin this bad boy climb non stop for months smfh! finally grabbed 1500 shares!!!!

AnaChart Posted - 3 weeks ago

$BDTX https://anachart.com/wp-content/uploads/ana_temp/1712592108_soc-img.jpg

tradingtwenty Posted - 3 weeks ago

$BDTX has trended 16 times in the past 24 hours (based on 5 minute intervals). Latest press release on Apr 07, 2024 06:00 PM: Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC... Link: https://tradingtwenty.com/news/421339/black-diamond-therapeutics-presents-novel-real-world-evidence-of-the-evolving-egfr-mutation-landscape-in-nsclc-and-the-opportunity-for-bdtx-1535-in-an-oral-presentation-at-the-2024-american-association-of-cancer-research-annual-meeting

OpenOutcrier Posted - 3 weeks ago

$BDTX (+6.7% pre) Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting - GN https://ooc.bz/l/29703

DonCorleone77 Posted - 3 weeks ago

$BDTX 3 of 3 - Black Diamond Therapeutics presents preclinical data on BDTX-1535 at AACR ....Preclinical data show that BDTX-1535 potently inhibits these co-expressed non-classical mutations. Phase 1 proof-of-concept data demonstrating durable responses in recurrent NSCLC patients with both non-classical and acquired resistance C797S mutations were presented in October 2023. Black Diamond is currently advancing BDTX-1535 in a Phase 2 trial for patients with EGFRm NSCLC across multiple lines of therapy. Patients are being enrolled both in a first-line setting (for those expressing EGFR non-classical mutations) and in second- and third-line settings following prior treatment with an EGFR inhibitor. Initial results from 2L/3L patients are anticipated in the third quarter of 2024.

DonCorleone77 Posted - 3 weeks ago

$BDTX 2 of 3 - Black Diamond Therapeutics presents preclinical data on BDTX-1535 at AACR ....Over 100 unique non-classical EGFR oncogenic driver mutations were identified in newly diagnosed patients with NSCLC, and these non-classical EGFR mutations were present in 20-30% of patients across all lines of treatment. Preclinical data demonstrated that BDTX-1535 potently inhibits more than 50 clinically relevant, non-classical EGFR mutations (as well as the classical L858R and exon19-del mutations) while sparing wild-type EGFR. The compound also potently inhibits the drug resistance C797S mutation, which emerges following treatment with third-generation EGFR inhibitors, including osimertinib. Real-world data indicate non-classical EGFR mutations can be co-expressed with classical mutation L858R, a setting that has been characterized by shorter duration of response to osimertinib first-line therapy....

DonCorleone77 Posted - 3 weeks ago

$BDTX 1 of 3 - Black Diamond Therapeutics presents preclinical data on BDTX-1535 at AACR Black Diamond Therapeutics presented real-world evidence of the evolving epidermal growth factor receptor mutation landscape in non-small cell lung cancer, and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies. The results were disclosed in an oral presentation on April 7 at the 2024 American Association of Cancer Research Annual Meeting held in San Diego, California. The oral presentation, titled "BDTX-1535 - A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical and the C797S Resistance Mutation to Address the Evolved Landscape of EGFR Mutant NSCLC," evaluated more than 235,000 sequenced cases of NSCLC sourced from Guardant Health and Foundation Medicine. The analyses reveal a broad spectrum of non-classical mutations, as well as an increased prevalence of the acquired resistance mutation, C797S....